Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galera Therapeutics Inc GRTX

Healthcare Biotechnology
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in... see more

Recent & Breaking News (OTCPK:GRTX)

Galera Announces Board Approval of Complete Liquidation and Dissolution

GlobeNewswire August 14, 2024

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

GlobeNewswire May 13, 2024

Galera Adopts Limited Duration Stockholder Rights Agreement

GlobeNewswire May 3, 2024

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

GlobeNewswire March 28, 2024

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

GlobeNewswire November 14, 2023

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

GlobeNewswire October 31, 2023

Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

GlobeNewswire September 18, 2023

Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

GlobeNewswire August 14, 2023

Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

GlobeNewswire August 9, 2023

Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

GlobeNewswire June 5, 2023

Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer

GlobeNewswire May 18, 2023

Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates

GlobeNewswire May 11, 2023

Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 4, 2023

Galera Expands Commercial Leadership Team

GlobeNewswire May 1, 2023

Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 26, 2023

Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology

GlobeNewswire March 10, 2023

Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

GlobeNewswire March 8, 2023

Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants

GlobeNewswire February 15, 2023

Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis

GlobeNewswire February 15, 2023